3[1]Burroughs A,Hochhauser D,Meyer T.Systemic treatment and liver transplantation for hepatocellular carcinoma:two ends of the therapeutic spectrum.Lancet Oncol 2004; 5:409-418
5[3]Torimura T,Sata M,Ueno T,Kin M,Tsuji R,Suzaku K,Hashimoto O,Sugawara H,Tanikawa K.Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma.Hum Pathol 1998; 29:986-991
6[4]Yamaguchi R,Yano H,Iemura A,Ogasawara S,Haramaki M,Kojiro M.Expression of vascular endothelial growth factor in human hepatocellular carcinoma.Hepatology 1998; 28:68-77
7[5]Kenyon BM,Browne F,D'Amato RJ.Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.Exp Eye Res 1997; 64:971-978
8[6]Peuckmann V,Fisch M,Bruera E.Potential novel uses of thalidomide:focus on palliative care.Drugs 2000; 60:273-292
2Chang JY, Ka WS, Chao TY, et al. Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review [J]. Oncology, 2004,67 (3-4) :320-326.
3Demeria D, Birchall I, Bain VG. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy [J]. Can J Gastroenterol,2007,21 (8) :517-518.
5Patt YZ, Hassan MM, Lozano RD, et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide[J]. Am J Clin Onco1,2000,23 ( 3 ) :319-321.
6Jeong W, Chun HG, Cer D, et al. A combination ot capecitabine and thalidomide in patients with hepatocellular carcinoma [J]. J Clin Oncol, 2006,24(18S) :a 4142.
7Ang SF, Tan SH, Toh HC, et al. Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma [J/OL]. Am J Clin Oncol,2011 [2011-07-10]. http://www. ncbi, nlm. nih. gov/pubmed/21378539.
